Beam Therapeutics says a single infusion of its experimental gene-editing treatment let two of three people with a rare inherited disease stop taking the daily starch they normally depend on to keep their blood sugar from crashing1. The Cambridge, Massachusetts company released the first results from its early trial on October 27, 2026, ahead of a poster presentation at the annual congress of the European Society of Gene and Cell Therapy in Hamburg, Germany1. The results come from six patients, with no comparison group, and four of the six had serious side effects that doctors linked to the treatment2.
What happened
The treatment, called BEAM-301, is aimed at glycogen storage disease type 1a, often shortened to GSD1a1. People with this disease keep only a limited ability to make their own sugar between meals3. To avoid low blood sugar, patients in this trial were taking 5 to 7 starch doses a day before treatment1.
BEAM-301 is built to fix one specific spelling mistake in a gene, known as R83C, which Beam calls one of the most common disease-causing mutations in GSD1a and one linked to the most severe form1. It uses base editing, a method that changes a single “letter” of DNA without cutting through both strands, a bit like fixing a typo instead of tearing out the page45. The editing tools are packed into tiny fat bubbles (lipid nanoparticles) that travel to the liver after an IV drip16.
As of an August 17, 2026 data cutoff, six adults had been treated: three at a 20 mg dose and three at 40 mg1. They had been followed for a median of 7.6 months, ranging from 1.9 to 16.6 months1.
The evidence so far
The trial’s main measure of blood sugar control is how long a person can fast under supervision before their blood sugar drops too low1. The company reported these results:
- Higher dose (40 mg): median fasting time rose from 2.5 hours before treatment to 15.0 hours at day 361.
- Lower dose (20 mg): median fasting time rose from 2.9 hours to 4.3 hours at day 361.
- Reaching the cap: two of the three higher-dose patients fasted for 15 hours, the longest the trial’s fasting test allows, and their blood sugar generally stayed in the normal range during those tests1.
- Starch: starch use generally went down after treatment, and the same two higher-dose patients no longer needed starch at their latest check1.
- Daily glucose: continuous glucose monitors, small sensors worn on the skin, showed more time in the normal range and less time too high, even with less starch, and patients generally did not spend more time too low1.
Not every patient improved. One person at the higher dose showed no gain in fasting time at the first check after treatment1. Beam said several factors may have played a part, including a higher body mass index and the fact that this patient carried only one copy of the targeted mutation1.
The presenting investigator, Rebecca Riba-Wolman, who directs the glycogen storage disease program at Connecticut Children’s, said in the company’s release:
“While these are early results, the improvements in glucose regulation and reductions in starch requirements provide encouraging evidence of BEAM-301’s potential to deliver meaningful and lasting benefits for patients.”
Side effects
All six patients had at least one side effect that doctors considered related to the treatment1. Four of six had serious related side effects, including three severe (Grade 3) reactions during the infusion1. Beam said the steroid medicines given beforehand may have contributed to those reactions, and it has since changed both the steroid plan and how fast the infusion runs1. Two other serious events, diarrhea and rhabdomyolysis (a breakdown of muscle tissue), occurred in two patients and both resolved1.
Liver enzyme levels, a common sign of liver stress, rose mildly in most cases, with one moderate rise; all returned to normal without treatment, and bilirubin stayed normal1. No one had a side effect severe enough to stop dose escalation, no one had a life-threatening or fatal event, and no one left the trial because of side effects1. Beam described the safety profile as consistent with other treatments delivered in fat bubbles1.
What it does not show yet
The trial is open-label, meaning patients and doctors know who got the treatment, and there is no placebo group to compare against7. It is mainly a safety study: its primary goal is to count side effects through month 24, while fasting time and starch use are secondary measures6. The results so far cover six people, with as little as about two months of follow-up for some1.
The data have been shared in a company release and a conference poster, not a peer-reviewed paper1. Because the fasting test stops at 15 hours, it cannot show whether the two best responders could go longer1. It is also not yet known how long the effect lasts, whether the one non-responder will improve later, or how the treatment will work in people with other mutations, since the trial only enrolls people who carry R83C7.
Who is behind it
Beam Therapeutics sponsors and pays for the trial7. The company first named BEAM-301 as a development candidate in January 2022, when it called GSD1a a life-altering genetic disease with no approved treatments that change its course5. The trial started on December 6, 2024, aims to enroll 36 adults, and lists three US sites in Orange, California; Farmington, Connecticut; and Houston, Texas6. Its primary completion date is listed as December 30, 20277.
Beam reported $1.2 billion in cash and securities as of March 31, 2026, which it said would fund operations into mid-20294. BEAM-301 is one of several base-editing programs at the company, alongside a liver-targeted treatment for alpha-1 antitrypsin deficiency and a sickle cell therapy for which it expects to seek approval as early as the end of 20264. On October 13, an earlier Beam report had said two evaluable higher-dose patients reached at least 15 hours of fasting2. Beam shares rose about 4.6% on the day of the new release2.
How it fits the field
Beam is not the only company trying to fix the root cause of GSD1a. Ultragenyx has run trials, including a late-stage one, of a gene therapy that uses a harmless virus to deliver a working copy of the missing glucose-6-phosphatase gene6. A Dutch research team has noted that both virus-based gene therapy and mRNA therapy are being developed for the disease, and has tested ways to measure how much sugar patients’ bodies make on their own3. Beam’s approach differs because it tries to correct the patient’s own gene in place with one dose, rather than add a new copy15.
Biohack recently reported on a related one-time gene fix for another inherited liver disease: a first patient treated for Wilson’s disease.
What to watch next
Based on the results so far, Beam has started enrolling a third group at a higher 60 mg dose1. The company says it plans to talk with the US Food and Drug Administration about a possible path to approval1, though it has not described what that path would look like. Key questions for the next update: whether the higher dose helps more patients, including those with only one copy of the mutation; whether the severe infusion reactions drop under the new steroid and infusion plan; and whether the two patients off starch stay that way over longer follow-up.
